Monday, December 04, 2023


“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

Goldman Sachs Exposes the Cure Dilemma

mapping out medical cures

Story Highlights

  • New gene therapies offer unprecedented hope for permanent cures of serious diseases and hold the promise of an invaluable societal impact.
  • In a report to their biotech clients, investment giant Goldman Sachs questions whether curative therapies are a viable business model.
  • Using Gilead Science’s hepatitis C drug as an example, the report noted curing existing patients also reduced the potential for infecting a new generation of patients.

As reported by CNBC,1 a long-hushed fact of the industry has finally been brought to light in a report to clients by investment firm Goldman Sachs. In a report to their biotech clients, entitled “The Genome Revolution,” analysts note that from a purely financial perspective, The fact that “there is a lot less money in curing people than in long-term management of disease,” is particularly relevant now that new technologies hold the promise of a cure for many chronic serious diseases.2

In the version of the report available to the general public, Salveen Richter of Goldman Sachs Research3 discussed the cure potential for several cutting-edge technologies including gene therapy, gene editing and cell engineering, saying that such advances are changing the face of medicine.  This report comes at a time when new drugs in the field of so-called “genomic medicine” are rapidly entering the marketplace. Targeting such disorders as rare types of blindness and many cancers, these technologies aim to repair these conditions at the source, offering the promise of curative therapies previously undreamed of.

What is Genomic Medicine?

Three interrelated but distinct technologies include gene therapy, in which defective genes specific to a particular disorder are identified and either repaired or replaced; cell therapy, or genetically engineered cancer therapy, in which the patient’s own T-cells (immune system fighter cells) are engineered to be better able to target and fight their cancer cells when re-introduced into the body; and gene editing, which Richter describes as a sort of “molecular scissors” in which defective or missing genes can be repaired or replaced. The video also lights on the huge potential societal impact of these potentially curative therapies.

Billions of Dollars at Stake

There is no mention of the financial implications of these potentially curative technologies in the currently available video, except to make note of the fact that “genomic medicine is on track to “hit a five trillion dollar total addressable market.”4 However, CNBC, which reportedly accessed the original investor’s report, said that analysts also alluded to the immense success of Gilead Science’s hepatitis C drug Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), pointing out that the ability to cure 90 percent of sufferers had the ultimate effect of drying up the market.

Even aside from curing those who had previously required chronic care, curing the infection in existing patients also means there are fewer carriers to generate future hepatitis C patients. U.S. sales of the hepatitis therapy hit $12.5 billion in 2015, but have been falling since and are expected to peak at about four billion this year. CNBC quoted Richter as saying, “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”

Several suggestions were offered as potential solutions. First, it was suggested that research focus on large or growing “markets.” It was noted, for example, that hemophilia is a greater than nine billion dollar market with a six to seven percent annual growth rate. Second, the focus should be on more common disorders such as spinal muscular atrophy, which would provide a bigger pool of patients. Finally, the need for constant innovation and expansion was stressed, with the message that “future programs can offset the declining revenue trajectory of prior assets.”5


6 Responses

  1. so basically, with hold the cure so the companies can continue to make money on the sick. which then leads to only allowing the cure to those they see fit, such as family and personal friends, leaving the rest of society to sicken and or die…

  2. Here’s a thought: Remove “healthcare” from the list of economy-driving industries. What kind of person invests in the probabilities of poor health outcomes in fellow citizens? An opportunist.

  3. Find a good Functional medicine physician, work with them on detox, eating and lifestyle changes, and you won’t need to be concerned with treating chronic disease

  4. I shudder to think of the damage that these ‘new’ therapies created by the same system that created vaccines —recommended but voluntary for a time, then gradually mandated despite scientific evidence —will do. When genes are altered, they change the dna in every cell in a body over time as the normal replication process goes on. So will the blood of those ‘engineered’ people be controlled under the patents like gmo law and economy in other non-human applications currently in place? This ‘science’ is also modifying & experimenting with combining nonhuman genetic material to join certain desired animal features with human. So will the receivers of such therapy still be descendants of Adam or a man-beast type? We’re not talking human to human blood transfusions here, or even organ transplants, which still do not alter the entire genetic makeup of the individuals receiving them as this so-called gene therapy does. Will their children carry traits of the bestial genetics that could show up in surprising and disturbing ways? Are the government and corporate steered and controlled scientists gods with a track record of not making mistakes in applications MUCH less complicated than the still not fully understood mechanisms of dna? The implications of this research are disturbing —much of it driven by the military and industrial complexes looking for super-soldiers &-workers. It reminds me of the ancient practice of making eunuchs of certain servants, and the ancient deceptive craft of control by a minority elite & its rewarded managers over the masses conditioned to blind obedience. Pyramidal and tyrannical. They can call it ‘kinder’, ‘gentler’, ‘tolerant’ or ‘new’ if they want to: I say it is still lying, unkind, wickedly violent, intolerant of truth and right, and as old as Genesis 3 and pushing blindly toward the prophesied end of the biblical Christian era for an idolatrous disaster that only Christ’s return in judgment can halt or restore to conditions necessary to temporal life or freedom. Talk about an irreversible ‘mark’!

    The thought of the pattern of mandating such ‘therapies’ as was done with vaccines in this case: of mandating an even more invasive form of therapy changing the body at the deepest & most comprehensive way like this are mind-boggling. Imagine if vaccines had done that across the board & there was no way to detox or counter the damage whether intended or not among those that survived the bad reactions! No. thank. you.

    The way in which it is being presented is also suspect: what a terrific dialectic steering maneuver to suddenly open up the discussion on vaccines, ramping up dissent publicly as though it mattered —though all the old, most heavily documented scientific dissenting voices are suspiciously & suddenly nowhere to be found in the ‘conversation’. Then at just the right moment, just the right ‘crisis’, they can spring this wonderful ‘solution’ to the whole problem & look like heroes as they turn partially educated & conditioned people to the ‘new’ thing that’s even worse.

Leave a Reply

Your email address will not be published. Required fields are marked *

Search in Archive

Search in Site

To search in site, type your keyword and hit enter